

Revolutionizing CRC Diagnostics KRAS **BRAF**



YOUR PATIENTS, **OUR PRIORITY**

Guiding Them to the Right Therapy within Hours



Idylla™ - Revolutionizing CRC Diagnostics Speed up your therapy decisions and alleviate patient anxiety¹

Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy.

MSI

KRAS

NRAS

BRAF



Idylla™ - Because time matters



Get actionable biomarker results in only 3 hours, instead of days or weeks as with NGS.



Rapidly identify your patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay.²



Idylla™ enables you to practice precision medicine according to international guidelines (ESMO).²

Idylla™ - A technology you can rely on

- ✓ Strong scientific evidence (>200 publications)
- ✓ Proven high performance
- ✓ Low failure rate
- ✓ CE-IVD



ff Idylla[™] enables rapid access to the right test at the right time to improve patient care.

Dr. Toby Talbot, Consultant Clinical Oncologist, Royal Cornwall Hospital, UK

Biocartis NV Mechelen, Belgium +32 15 632 888 www.biocartis.com customerservice@biocartis.com

Follow us on **f**Xin

- (1) Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.
- (2) Cervantes, et al. (2023). Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology,* 34(1), 10-32

CRC: Colorectal Cancer

Idylla™ Platform, Idylla™ MSI Test and Idylla™ KRAS & NRAS-BRAF Mutation Tests are CE-marked in Europe in compliance with EU IVD directive 98/79/EC. Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. © August 2024, Biocartis NV. All rights reserved.